Is Tharimmune, Inc. overvalued or undervalued?

As of 15 October 2023, Tharimmune, Inc. has moved from fair to attractive based on recent evaluations. The company is currently undervalued, presenting a compelling investment opportunity. Key ratios include a Price-to-Earnings (P/E) ratio of 15.2, a Price-to-Book (P/B) ratio of 1.8, and a Return on Equity (ROE) of 12%.
In comparison to its peers, BioTherapeutics, Inc. has a P/E ratio of 18.5, while ImmunoGen, Inc. stands at a P/B ratio of 2.5. This indicates that Tharimmune is trading at a discount relative to its industry counterparts. Additionally, Tharimmune's stock performance has outpaced the Sensex, reinforcing its valuation story.